Bone Biologics FY2026 EPS Forecast Reduced by Zacks Research

Bone Biologics Corp. (NASDAQ:BBLG) – Analysts at Zacks Research lowered their FY2026 earnings per share (EPS) estimates for Bone Biologics in a note issued to investors on Tuesday, March 3rd. Zacks Research analyst B. Sorensen now expects that the company will earn ($1.93) per share for the year, down from their previous estimate of ($1.36). The consensus estimate for Bone Biologics’ current full-year earnings is ($5.00) per share.

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Bone Biologics in a report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Bone Biologics Trading Down 2.4%

Shares of Bone Biologics stock opened at $1.22 on Thursday. Bone Biologics has a 1 year low of $1.11 and a 1 year high of $6.75. The company’s fifty day simple moving average is $1.46 and its 200-day simple moving average is $1.86. The company has a market cap of $2.20 million, a price-to-earnings ratio of -0.32 and a beta of 0.78.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC boosted its holdings in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,576 shares of the company’s stock after buying an additional 12,549 shares during the period. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 34.30% of the company’s stock.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.